Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | WEE1 | P30291 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1480947 | 1.00 | FFAR4 (0.40) | FFAR4FFAR1CYSLTR2CYSLTR1SRC | |
| SCHEMBL1480640 | 0.95 | MAPT (0.39) | FFAR4FFAR1CYSLTR2CYSLTR1MAPT | |
| SCHEMBL1481641 | 0.95 | MAPT (0.39) | FFAR4FFAR1CYSLTR2CYSLTR1MAPT | |
| SCHEMBL12735982 | 0.93 | CYSLTR2 (0.42) | FFAR4FFAR1CYSLTR2CYSLTR1FABP3 | |
| SCHEMBL1480599 | 0.90 | FFAR4 (0.41) | FFAR4FFAR1CYSLTR2CYSLTR1FABP3 | |
| SCHEMBL1480598 | 0.90 | FFAR4 (0.41) | FFAR4FFAR1CYSLTR2CYSLTR1FABP3 | |
| SCHEMBL1481305 | 0.90 | MAPT (0.39) | FFAR4FFAR1CYSLTR2CYSLTR1MAPT | |
| SCHEMBL1481302 | 0.90 | MAPT (0.39) | FFAR4FFAR1CYSLTR2CYSLTR1MAPT | |
| SCHEMBL1480626 | 0.85 | THRB (0.39) | FFAR4FFAR1CYSLTR2CYSLTR1SRC | |
| SCHEMBL1480631 | 0.85 | THRB (0.39) | FFAR4FFAR1CYSLTR2CYSLTR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | FFAR4 2604/4885FFAR1 1810/4885CYSLTR2 2986/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | FFAR4 2384/4885FFAR1 1602/4885CYSLTR2 2870/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | FFAR4 2604/4885FFAR1 1810/4885CYSLTR2 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.